key: cord-1009667-tu5wlwtc
authors: Coryell, Michael P; Iakiviak, Mikhail; Pereira, Nicole; Murugkar, Pallavi P; Rippe, Jason; Williams, David B; Heald-Sargent, Taylor; Sanchez-Pinto, L Nelson; Chavez, Jairo; Hastie, Jessica L; Sava, Rosa L; Lien, Christopher Z; Wang, Tony T; Muller, William J; Fischbach, Michael A; Carlson, Paul E
title: A method for detection of SARS-CoV-2 RNA in healthy human stool: a validation study
date: 2021-03-31
journal: Lancet Microbe
DOI: 10.1016/s2666-5247(21)00059-8
sha: 59c19f202e3142bbf79e9e47461d6d463b0ce7c0
doc_id: 1009667
cord_uid: tu5wlwtc

BACKGROUND: Faecal shedding of SARS-CoV-2 has raised concerns about transmission through faecal microbiota transplantation procedures. Validation parameters of authorised tests for SARS-CoV-2 RNA detection in respiratory samples are described in product labelling, whereas the published methods for SARS-CoV-2 detection from faecal samples have not permitted a robust description of the assay parameters. We aimed to develop and validate a test specifically for detection of SARS-CoV-2 in human stool. METHODS: In this validation study, we evaluated performance characteristics of a reverse transcriptase real-time PCR (RT-rtPCR) test for detection of SARS-CoV-2 in human stool specimens by spiking stool with inactivated SARS-CoV-2 material. A modified version of the US Centers for Disease Control and Prevention RT-rtPCR SARS-CoV-2 test was used for detection of viral RNA. Analytical sensitivity was evaluated in freshly spiked stool by testing two-fold dilutions in replicates of 20. Masked samples were tested by a second laboratory to evaluate interlaboratory reproducibility. Short-term (7-day) stability of viral RNA in stool samples was assessed with four different stool storage buffers (phosphate-buffered saline, Cary-Blair medium, Stool Transport and Recovery [STAR] buffer, and DNA/RNA Shield) kept at −80°C, 4°C, and ambient temperature (approximately 21°C). We also tested clinical stool and anal swab specimens from patients who were SARS-CoV-2 positive by nasopharyngeal testing. FINDINGS: The lower limit of detection of the assay was found to be 3000 viral RNA copies per g of original stool sample, with 100% detection across 20 replicates assessed at this concentration. Analytical sensitivity was diminished by approximately two times after a single freeze-thaw cycle at −80°C. At 100 times the limit of detection, spiked samples were generally stable in all four stool storage buffers tested for up to 7 days, with maximum changes in mean threshold cycle values observed at −80°C storage in Cary-Blair medium (from 29·4 [SD 0·27] at baseline to 30·8 [0·17] at day 7; p<0·0001), at 4°C storage in DNA/RNA Shield (from 28·5 [0·15] to 29·8 [0·09]; p=0·0019), and at ambient temperature in STAR buffer (from 30·4 [0·24] to 32·4 [0·62]; p=0·0083). 30 contrived SARS-CoV-2 samples were tested by a second laboratory and were correctly identified as positive or negative in at least one of two rounds of testing. Additionally, SARS-CoV-2 RNA was detected using this assay in the stool and anal swab specimens of 11 of 23 individuals known to be positive for SARS-CoV-2. INTERPRETATION: This is a sensitive and reproducible assay for detection of SARS-CoV-2 RNA in human stool, with potential uses in faecal microbiota transplantation donor screening, sewage monitoring, and further research into the effects of faecal shedding on the epidemiology of the COVID-19 pandemic. FUNDING: National Institute of Allergy and Infectious Diseases, US National Institutes of Health; Center for Biologics Evaluation and Research, US Food and Drug Administration.

Faecal microbiota transplantation (FMT) is of interest as a treatment for numerous conditions associated with dysbiosis of the gut microbiome, the most well studied of which is the treatment of recurrent Clostridioides difficile infection. 1 The screening process for stool donors includes stool and blood testing to minimise the potential for transmission of pathogens of concern. 2 Testing recom mendations for stool donors are expected to change over time, particularly as new pathogens emerge. In 2020, the US Food and Drug Administration (FDA) issued safety alerts indicating the need for increased donor screening or changes in donor testing methods, including tests for multidrugresistant organisms, enteropathogenic Escherichia coli, and Shiga toxinproducing E coli. 3, 4 The emergence and global spread of COVID19 and the discovery of SARSCoV2 in the stool of infected individuals has led to concerns regarding the possibility of SARSCoV2 transmission via FMT. [5] [6] [7] [8] In response to early reports of faecal shedding, the FDA issued a safety alert on March 23, 2020 (updated on April 9, 2020) , to indicate that there should be no clinical use of FMT products manufactured from stool donated on or after Dec 1, 2019, until additional screening and testing procedures had been implemented for donor qualification programmes. 9, 10 This safety alert suggested possible methods for assessing donors and donor stool, including routine nasal testing of donors and direct testing of donor stool for the virus. Although the FDA has authorised many molecular diagnostic tests for detection of SARSCoV2 in respiratory and oral specimen types under an emergency use authorisation (EUA), no molecular tests with stool as the specimen type have received an EUA. Three publications have provided an assessment of methods for detection of SARSCoV2 RNA in stool, [11] [12] [13] but a stool assay with a demonstrated ability to detect SARSCoV2 RNA in healthy human stool with high sensitivity, with validation meeting the requirements for an FDA EUA application, has not yet been reported. We aimed to develop and validate an assay to reliably detect SARSCoV2 RNA in stool samples without reliance on specialised testing platforms or proprietary testing kits and also to provide data regarding SARSCoV2 stability in stool under different storage conditions.

In this validation study, we evaluated the performance characteristics of a reverse transcriptase realtime PCR (RTrtPCR) test for detection of SARSCoV2 in human stool specimens by spiking stool with inactivated SARSCoV2.

Heatinactivated SARSCoV2 was used for spikein experiments to facilitate safe handling. Virus stocks were propagated in vitro under biosafety level 3 conditions (appendix 1 p 1) and harvested supernatants were inactivated in a water bath at 60°C for 1 h. Inactivated stocks were diluted in sterile phosphatebuffered saline (PBS; Gibco, Gaithersburg, MD, USA), aliquoted, and stored at -80°C. Subsequent experiments with this material were done under biosafety level 2 conditions. To minimise degradation from freeze-thaw activity, fresh freezer stocks were used for each experiment. Absolute concentrations of viral genome targets were quantified using droplet digital PCR (appendix 1 p 1). Initial RTrtPCR protocol development, limit of detection experiments, and subsequent experiments were done using human faecal material from a total of five donors purchased from two separate vendors (Lee Biosolutions, Maryland Heights, MS, USA, and OpenBiome, Somerville, MA, USA). All faecal samples were collected by the vendors with informed consent from healthy donors aged 18-50 years, with no use of antibiotics for at least 30 days before sample donation. To ensure SARSCoV2 negativity, only samples collected and frozen by the vendors before January, 2020, were purchased.

The protocols for isolation of viral RNA from stool samples and RNA target detection were adapted from previously published work. 11 Whole stool was diluted 1:5 (weight per volume) in sterile PBS, homogenised, and clarified by centrifugation at 4000 relative centrifugal force for 20 min at 4°C. 140 µL of clarified supernatant

Evidence before this study On Feb 1, 2021, we searched PubMed for articles published since database inception, in any language, using the terms ("SARS-CoV-2" OR "COVID-19") AND ("feces" OR "stool"). Our search identified multiple studies that have documented shedding of SARS-CoV-2 RNA in faeces and considered the potential for faecal-oral transmission of the virus. This potential risk led the US Food and Drug Administration (FDA) to issue a safety alert on March 23, 2020 (updated on April 9, 2020), recommending that stool donated after Dec 1, 2019, should be quarantined and not used for manufacture of faecal microbiota transplantation (FMT) products in the USA until sufficient screening procedures could be put in place to mitigate this risk. The addition of the term ("validated" OR "validation") into our search yielded only 11 results, including many studies related to wastewater testing methods. Two studies assessed stool testing with some reference to validation, but neither study provided full validation according to the current FDA emergency use authorisation guidelines for COVID-19 respiratory diagnostics. We were also unable to find any studies assessing SARS-CoV-2 detection in healthy stool or the effects of storage conditions on the assay performance.

We report the development and validation of an assay for the detection of SARS-CoV-2 RNA in the stool of healthy individuals. This assay does not rely on proprietary primer and probe sets or specialised testing platforms and was validated using inactivated SARS-CoV-2 spiked into healthy human stool specimens from multiple donors. Additionally, we provide data on viral stability in stool stored at various temperatures and in different transport media and assess the use of the method by testing it on stool and anal swabs from individuals with previous SARS-CoV-2-positive nasopharyngeal tests.

We describe a validated SARS-CoV-2 stool assay with potential applications in FMT donor screening protocols, sewage monitoring protocols, and research studies assessing the role of stool shedding and transmission on the epidemiology of COVID-19. With minimal use of proprietary reagents or specialised equipment, this stool testing protocol is easily implemented at other laboratories, potentially improving the availability of other laboratory-developed testing protocols.

See Online for appendix 1 was used as starting material for RNA extraction using the QIAamp Viral RNA mini kit (Qiagen, Germantown, MD, USA) spincolumn protocol, with a final elution volume of 50 µL.

For detection of SARSCoV2 viral RNA, extracted RNA was tested via onestep RTrtPCR using 2019_nCoV RUO testing kits (Integrated DNA Technologies, Coralville, IA, USA) with a modified thermal cycling protocol (appendix 1 pp 1-2). The assay uses three sets of sequencespecific primers and fluorescent hydrolysis probes described in the SARSCoV2 US Centers for Disease Control and Prevention (CDC) EUA protocol (appendix 1 p 3). 14 Two of the primer and probe sets, 2019_nCOV_N1 (N1) and 2019_nCOV_N2 (N2), target conserved regions within the nucleocapsid gene. A third set, targeting the human ribonuclease P (RNase P; RPP30) gene was used as an internal amplification and sample adequacy control. For this testing protocol, amplification of either the N1 or N2 viral targets with a threshold cycle (Ct) of less than 40·0 was considered SARSCoV2 positive. Samples were classified as negative when neither N1 and N2 amplified with Ct of less than 40·0 whereas the RNase P gene target was successfully detected with Ct of less than 40·0. Samples in which none of the targets amplified with Ct less than 40·0 were considered invalid.

An approximate range for the expected limit of detection was determined by testing stool specimens spiked with a tenfold dilution series of heatinactivated SARSCoV2 material. Negative stool slurries from two independent donors were spiked with heatinactivated SARSCoV2 reference material from a twofold dilution series and tested in replicates of 20 (ten per donor stool), including independent RNA extraction for each replicate. At least one unspiked stool from each donor was tested with each batch of extractions as a negative specimen control, along with notemplate controls and positive controls for each reaction. The limit of detection was defined as the lowest concentration at which at least 95% of samples tested positive.

Leftover spiked stool material from these dilutions was stored at -80°C and later tested to investigate the effects of freezing SARSCoV2positive samples at or near the limit of detection. Frozen samples at one and two times the empirical limit of detection were thawed and tested in replicates of eight (four per donor) to determine the effect of freeze-thaw activity on lowcopynumber specimens.

24 positive specimens and six negative specimens (from a single donor during four different donations) were evaluated in duplicate rounds of testing. Positive specimens were contrived by spiking heatinactivated SARSCoV2 reference material into a negative stool matrix at one, two, five, and ten times the limit of detection (six samples per concentration). Samples were prepared at the FDA (Silver Spring, MD, USA) and shipped overnight on dry ice to Stanford University (Stanford, CA, USA). All samples were analysed in duplicate according to the aforementioned testing protocols. The recipient laboratory was masked to the spikein status of the specimens. Testing at Stanford University was done on the 7900 HT Fast Realtime PCR system (Applied Biosystems, Foster City, CA, USA).

Additionally, stool and anal swab specimens were obtained from paediatric patients with recent SARSCoV2positive respiratory tests (in the previous 0-13 days). Samples were collected after obtaining verbal assent from patients and written consent from the patients' parents under protocols approved by the institutional review board of Ann & Robert H Lurie Children's Hospital (Chicago, IL, USA). RNA was extracted from stool at the Ann & Robert H Lurie Children's Hospital and shipped overnight on dry ice to the FDA for RTrtPCR analysis.

The stability of SARSCoV2 RNA was tested in stool stored in different buffers and at different temperatures. Four storage media were tested: PBS, CaryBlair medium (appendix 1 p 2), Roche Diagnostics Stool Transport and Recovery (STAR) buffer (Fisher Scientific, Hampton, NH, USA), and DNA/RNA Shield (Zymo Research, Irvine, CA, USA). Stool slurries in each buffer (1·5 g of stool to 5 mL of buffer) were spiked with approximately 100 times the limit of detection of inactivated SARSCoV2. Aliquots of each slurry were stored at -80°C, 4°C, or ambient temperature (approximately 21°C). RNA was extracted from each set of samples immediately (day 0) and on days 1, 2, 3, and 7 of storage at 4°C and ambient temperature, and on day 7 only from samples stored at -80°C. Extracted RNA was stored at -80°C until the end of the experiment, when RTrtPCR was done in duplicate using only the N1 target because it was more sensitive than the N2 target in previous experiments. This experiment was replicated using independently collected stool samples from the same donor, for a total of two biological replicates.

Mean sample Ct values and SDs were calculated in Microsoft Excel version 1902, and were inclusive of any detected Ct values, regardless of whether they met the 40 Ct cutoff for positive determination. We also calculated 95% CIs for mean Ct values in GraphPad Prism version 8.4.0 (GraphPad Software, La Jolla, CA, USA). Contrived clinical testing agreement rates (simple percentage agreement) and associated ClopperPearson 95% CIs were calculated using the Westgard QC online 2 × 2 contingency calcu lator tool. 15 Quantitative Ct comparisons were plotted and analysed in GraphPad Prism. Fresh and frozen Ct values were compared using a mixedeffects model with Sidak multiple comparison testing, treating fresh or frozen status and storage buffers as the fixed effects and replicate measurements as random effects. Ct values from 4°C and ambient temperature storage conditions were analysed using a mixedeffects model with GeisserGreenhouse correction and Dunnett's multiple comparison testing, treating storage conditions and sampling day as fixed variables and replicate measure ments as random effects. Clinical Ct values were compared between positive whole stool and anal swab specimen types using a twoway ANOVA for paired N1 and N2 measurements, with no further posthoc testing. We considered p values of less than 0·05 to be statistically significant, with multiplicityadjusted p values when appropriate.

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

We developed a protocol for an RTrtPCRbased assay for SARSCoV2 detection in stool samples and found its limit of detection to be 600 viral RNA copy equivalents per mL of stool matrix (table 1). After accounting for the 1:5 (weight per volume) stool dilution, this is equivalent to 3000 copies per g of whole stool using this extraction protocol. The test positivity rate was 19 (95%) of 20 replicates at a viral concentration of 1200 copies per mL of stool slurry, 20 (100%) of 20 at 600 copies per mL, and 14 (70%) of 20 at 300 copies per mL (table 1). The RNase P target was detected in all 20 replicates tested from each dilution, as well as in all negative specimen control extractions tested. At the limit of detection, N1 targets were positive in 19 (95%) of 20 replicates and N2 targets were positive in 16 (80%) of 20 replicates (table 1) . Of note, N2 amplification above baseline fluorescence was detected in all 20 samples, but only 16 met the criteria for positive detection (Ct<40·0). The limit of detection in samples frozen at -80°C was twice that in freshly spiked samples. After one freeze-thaw cycle, samples had a test positivity rate of six (75%) of eight at the limit of detection and of eight (100%) of eight at two times the limit of detection (table 2 ).

In the interlaboratory assessment, 30 contrived samples were tested at Stanford University. Only one was found to be invalid due to the nonamplification of all three targets after initial testing. Of the 29 valid test results, 22 of 24 spiked samples tested positive, and five of five negative samples tested negative, for an overall correct testing rate of 93·1% (95% CI 78·0-98·1) in 27 of 29 valid results. In a replicate round of testing for all samples, three of the contrived samples returned invalid results. Of the 27 valid replicate test results, 21 of 23 contrived positive samples tested positive and four of four negative samples tested negative, for an overall correct testing rate of 92·6% (76·6-97·9) in 25 of 27 valid results. All falsenegative tests were in the concentration range of one to two times the assay limit of detection, within which freezer storage can negatively affect SARSCoV2 detection (table 2) . Of note, no false positive test results occurred and none of the samples tested were invalid or falsely negative in both rounds of replicate testing.

The stability of SARSCoV2 RNA was evaluated in different storage buffers and at different temperatures. At baseline (day 0), the mean Ct value of spiked stool suspended in PBS was 28·8 (SD 0·13), in CaryBlair medium was 29·4 (0·27), in STAR buffer was 30·4 (0·24), and in DNA/RNA Shield was 28·5 (0·15). Comparing samples stored at -80°C for 1 week with their respective baseline values (figure part A), mean Ct values increased significantly to 29·7 (0·14) in PBS (p<0·0001) and to 30·8 (0·17) in CaryBlair medium (p<0·0001) but did not change significantly in STAR buffer (p>0·99) or DNA/RNA Shield (p>0·99).

Among samples stored at 4°C for up to 1 week, only those stored in DNA/RNA Shield had significant increases in Ct values above baseline, reaching significance on day 2 (p=0·0019) and a maximum mean Ct of 29·8 (SD 0·09) on Among specimens testing positive, we observed a wide range of Ct values for both the N1 (20·0-38·3) and N2 (21·2-39·6) gene targets. A narrower range was observed for the RNase P target (26·5-38·3) among all specimens. Mean Ct values were 28·7 (SD 4·6) for N1, 31·7 (5·1) for N2, and 31·6 (2·8) for RNase P. There was no significant difference in viral target Ct values between whole stool and anal swab specimen types (twoway ANOVA p=0·78).

Widely documented faecal shedding of SARSCoV2 viral RNA, sometimes in the absence of positive respiratory testing, has led to an interest in assessing viral loads in stool for a range of purposes, from diagnostics to environmental monitoring for rapid outbreak detection. [16] [17] [18] [19] Additionally, the potential for transmission of SARSCoV2 via stool has led to concerns regarding the possible transmission as part of an FMT procedure, particularly with the possi bility of asymptomatic shedding in stool. [20] [21] [22] [23] Therefore, SARSCoV2 testing needs to be incorporated into FMT donor screening protocols in the COVID19 era. 5, 6, 8 Here, we report the development and validation of a method for the detection of SARSCoV2 RNA in healthy human stool. We provide data indicating acceptable storage and transport conditions for material to be tested. Finally, we show the clinical application of this test in detection of SARSCoV2 RNA in the stool of infected 12, 13 Additionally, other published methods for detection of viral RNA in stool were developed or validated with reference materials other than full, intact, inactivated SARSCoV2, which is recommended in the latest FDA guidance on COVID19 diagnostics. 24 By contrast, using accurate reference materials, including human stool from healthy donors and heatinactivated SARSCoV2, we have shown sensitive and reproducible detection of SARSCoV2 RNA in stool using methods modified from the CDC RTrtPCR diagnostic protocol. 14 Importantly, over the course of all testing, heatinactivated SARSCoV2 was spiked into stool from five separate healthy individuals and no donorspecific signal loss was observed. The reported assay has a low limit of detection (3000 copies per g of stool), which is similar to other molecular tests used for detection of other enteric pathogens. 25 Further research is needed to understand the actual risk of faecal-oral transmission and the infectious dose of SARSCoV2 to fully evaluate the effectiveness of this assay. The assay was able to detect SARSCoV2 RNA in 22 (58%) of 38 stool samples from patients with confirmed SARSCoV2 infection by nasopharyngeal PCR test, emphasising the complexity between nasopharyngeal and faecal viral loads. In one metaanalysis of 95 different studies, only 43% of infected patients tested positive for SARSCoV2 in stool or anal swab specimens. 21 Thus, we did not expect all samples tested to find detectable amounts of SARSCoV2 RNA. Negative test results for stool samples included in this study could be due to either an absence of faecal shedding in those individuals or shedding at a level below the limit of detection of the assay. This discrepancy between nasopharyngeal and faecal positivity emphasises the limitations of stool testing for COVID19 diagnostic use. Of note, our samples came primarily from individuals with a positive nasopharyngeal test who were symptomatic. Although testing in asympto matic SARSCoV2positive individuals would have been ideal, we were unable to obtain samples from this group.

Without access to stool from these individuals, we did an interlaboratory assessment using contrived samples in lieu of a clinical performance study. To prevent bias, the secondary laboratory doing the tests was masked to the status of contrived SARSCoV2 positive and negative specimens. Replicate testing results showed the repro ducibility of this protocol between users in different laboratories. Although the blinded assessment did yield a small number of falsenegative results at low viral spikein loads, this was not unexpected based on our characteri sation of analytical sensitivity in frozen samples at or near the limit of detection. However, replicate testing improved detection sensitivity, because all samples tested correctly in at least one of two rounds of testing. This finding provides support for incorporating replicate testing for the detection of low viral copy numbers in stool testing protocols. More work is needed to determine the expected viral load range in a study population of asymptomatic individuals infected with SARSCoV2. Due to these limitations, this evaluation was not sufficiently powered for robust estimation of clinical sensitivity or specificity.

During the early stages of the COVID19 pandemic, high demand for testing reagents, as well as challenges with coldchain management, necessitated evaluation of alternate specimen collection media and storage condi tions. 26 With this in mind, we sought to assess the loss of sensitivity observed after storage in some conditions, which represents a potential limitation of this assay. We evaluated the stability of heatinactivated virusspiked stool samples, at a moderately high viral copy number, stored in four different buffers and at different temperatures (-80°C, 4°C, or ambient temperature). Detection of SARSCoV2 was consistent across all media and storage temperatures. However, variation in detection signal (Ct value) suggests that both stool transport and dilution media and sample storage temperature should be considered when developing protocols for collection, storage, and testing for SARSCoV2 RNA in stool. Among the media tested, DNA/RNA Shield performed best overall. Samples stored in DNA/RNA Shield showed improved stability compared with PBS and STAR buffer at ambient temperature and compared with PBS at -80°C. Of note, DNA/RNA Shield performed better at ambient temperature than at 4°C, which is consistent with the manufacturer's recom mendations for use and should be considered when using this product. CaryBlair medium, a common substrate for stool transport, provided the least protection from freezing but otherwise performed similarly to PBS at 4°C. The results after freezing of spiked stool samples did show potential negative effects on sample stability. Of note, freezer storage of spiked specimens reduced detection in samples with low copy numbers. This effect was also apparent in our reproducibility evaluation in which some frozen specimens with low copy numbers returned false negative results. Because we were unable to evaluate viral RNA stability in stool from known positive donors, we do Although transmission of SARSCoV2 via the faecaloral route or in FMT remains a topic of debate, evidence of gastrointestinal infection has been reported, including isolation of infectious virus from stool. 17, 20 Here, we present a technical validation of methods developed for testing stool for SARSCoV2 viral RNA. In contrast to other published testing protocols, we considered detection of either N1 or N2 target sufficient for a SARS CoV2 RNApositive test result, regardless of human RNase P amplification. Although some of our results were consistent with previous reports that the N1 primer and probe set is more sensitive than N2, 27 our data include several valid results which were N2 positive and N1 negative, supporting the continued use of N2 in SARS CoV2 testing. We did not investigate the use of alternative SARSCoV2 RTrtPCR primer and probe sets, nor did we explore alternative testing technologies. The data presented here show a validated stool detection method for SARSCoV2 RNA that has the potential for use in a variety of applications, including FMT donor screening, sewage monitoring, and clinical research.

MPC, JLH, WJM, and PEC designed the study. MPC did assay development, validation, and implementation. MPC, MAF, and PEC analysed the data. MI, NP, PPM, and MAF did secondary site implementation and testing. CZL and TTW generated inactivated virus used in the studies. JR, DBW, THS, LNSP, JC, and WJM acquired and processed clinical samples. MPC, JLH, RLS, WJM, and MAF assisted in manuscript preparation. MPC, JLH, and PEC verified all underlying data in the study. All authors had full access to all the data in the study, reviewed the final manuscript, and had final responsibility for the decision to submit for publication.

PEC reports grants from the National Institute of Allergy and Infectious Diseases, US National Institutes of Health, during the conduct of the study. All other authors declare no competing interests.

All data generated in these studies are available upon request made to the corresponding author.

Fecal microbiota transplantation: current applications, effectiveness, and future perspectives

Regulatory considerations for fecal microbiota transplantation products

Information pertaining to additional safety protections regarding use of fecal microbiota for transplantation-testing of stool donors for enteropathogenic Escherichia coli and Shigatoxinproducing Escherichia coli

Safety alert regarding use of fecal microbiota for transplantation and risk of serious adverse events likely due to transmission of pathogenic organisms

Reorganisation of faecal microbiota transplant services during the COVID19 pandemic

Fecal microbiota transplantation and donor screening for Clostridioides difficile infection during COVID19 pandemic

Screening of faecal microbiota transplant donors during the COVID19 outbreak: suggestions for urgent updates from an international expert panel

Screening faecal microbiota transplant donors for SARSCoV2 by molecular testing of stool is the safest way forward

Safety alert regarding use of fecal microbiota for transplantation and additional safety protections pertaining to SARSCoV2 and COVID19

Information pertaining to additional safety protections regarding use of fecal microbiota for transplantation-screening donors for COVID19 and exposure to SARSCoV2 and testing for SARSCoV2

Screening FMT donors during the COVID19 pandemic: a protocol for stool SARSCoV2 viral quantification

Validation of SARSCoV2 detection across multiple specimen types

Utility of stool PCR for the diagnosis of COVID19: comparison of two commercial platforms

Research use only 2019novel coronavirus (2019nCoV) realtime RTPCR primers and probes

Estimating clinical agreement for a qualitative test: a web calculator for 2x2 contingency table

SARSCoV2 RNA in wastewater anticipated COVID19 occurrence in a low prevalence area

Infectious SARSCoV2 in feces of patient with severe COVID19

Gastrointestinal manifestations of SARSCoV2 infection and virus load in fecal samples from a Hong Kong Cohort: systematic review and metaanalysis

Quantitative detection and viral load analysis of SARSCoV2 in infected patients

Evidence for gastrointestinal infection of SARSCoV2

Systematic review with metaanalysis: SARSCoV2 stool testing and the potential for faecaloral transmission

Mild and asymptomatic cases of COVID19 are potential threat for faecaloral transmission

COVID19: faecaloral transmission?

Policy for coronavirus disease2019 tests during the public health emergency (revised)

Multicenter evaluation of the BD max enteric bacterial panel PCR assay for rapid detection of Salmonella spp, Shigella spp, Campylobacter spp (C jejuni and C coli), and Shiga toxin 1 and 2 genes

Evaluation of transport media and specimen transport conditions for the detection of SARSCoV2 by use of realtime reverse transcriptionPCR

Analytical sensitivity and efficiency comparisons of SARSCoV2 RTqPCR primerprobe sets

This work was supported by an interagency agreement to PEC between the National Institutes for Health and the FDA (AAI17016-001-00001) and the Intramural Research Program of the Center for Biologics Evaluation and Research, FDA. This project was supported in part by an appointment to the Research Fellowship Program at the Office of Vaccines Research and Review/Center for Biologics Evaluation and Research, FDA, administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and FDA.